A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Phase 3
1,046
about 7.2 years
18+
36 sites in AZ, CA, CO +18
Why this study is shown
What this study is about
Researchers are testing if a new treatment combination with zilovertamab vedotin plus rituximab can help people live longer without the cancer growing or spreading than standard treatment alone. The trial will last for 2618 days and involve approximately 1046 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Rituximab
- 2.Receive Rituximab Biosimilar
- 3.Receive Zilovertamab vedotin
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), doxorubicin (Anthracycline chemotherapy; intercalates DNA and inhibits topoisomerase II), methylprednisolone, prednisolone, prednisone, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them), biologic (immunotherapy) (Monoclonal antibody; targets CD20 on B-cells to destroy them), vincristine
infusion, injection (Injection), oral (Disintegrating Oral Tablet), oral
Primary: Progression-free survival (PFS)
Secondary: Change From Baseline in HRQoL on FACT-Lym Physical Wellbeing (PWB) Score, Change From Baseline in HRQoL on FACT-Lym Total Score, Change From Baseline in HRQoL on Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX) Neurotoxicity Subscale Score, Change From Baseline in Health-Related Quality Of Life (HRQoL) on Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym) Trial Outcome Index (TOI) Score, Complete Response at End of Treatment (CR at EOT), Event-free Survival (EFS), Number of Participants Who Discontinue Study Treatment Due to an AE, Number of Participants Who Experience an Adverse Event (AE)
Oncology